MainPointe Pharma acquires several Mission Pharmacal OTCs
Mission Pharmacal on Wednesday divested several consumer products to MainPointe Pharmaceuticals along with the marketing rights of additional consumer products that have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewable contract manufacturing agreement to continue manufacturing all of the included products that are currently made in Mission’s manufacturing facility.
“These are exciting agreements that will provide consumers greater access to the products involved due to MainPointe’s existing relationships within more diverse distribution channels,” Neill Walsdorf, Jr., Mission president, said. “Mission remains passionate about the products involved, and more importantly, we are steadfast in our support of the end users who rely on these products every day.”
As part of the agreements, the Thera-Gesic, Thera-Gesic Plus, Dr. Smith’s Diaper Rash Ointment, Dr. Smith’s Diaper Rash Spray, Dr. Smith’s Adult Barrier Spray and Dr. Smith’s Adult Ointment have been divested.
In addition, marketing rights have been licensed by Mission to MainPointe for the following Calcet, Fosfree, Heat Guard, Maxilube and Lycelle Head Lice Removal Kit.
“We look at these agreements as the beginning of an exciting strategic partnership between Mission and MainPointe,” Walsdorf said. “Our industry is continually evolving and we hold strong to the belief that partnering for success is more essential today than ever before.”
The new portfolio of products joins Nexafed and Nexafed Sinus as core MainPointe Pharmaceuticals OTC products being supplied by the manufacturer. This past fall, MainPointe acquired the rights to these popular diversion-resistant cough/cold products from Acura Pharmaceuticals.
As part of that deal, MainPointe brought Nexafed 2.0 to market late last year.
"Conversion of pseudoephedrine products into methamphetamine remains an acute problem in many communities," John Schutte, MainPointe chairman and CEO, said when MainPoint first acquired the rights to market Nexafed. "The Nexafed products have proven to be a success in curbing this costly problem and we look forward to driving this business forward."
“These are exciting agreements that will provide consumers greater access to the products involved due to MainPointe’s existing relationships within more diverse distribution channels,” Neill Walsdorf, Jr., Mission president, said. “Mission remains passionate about the products involved, and more importantly, we are steadfast in our support of the end users who rely on these products every day.”
As part of the agreements, the Thera-Gesic, Thera-Gesic Plus, Dr. Smith’s Diaper Rash Ointment, Dr. Smith’s Diaper Rash Spray, Dr. Smith’s Adult Barrier Spray and Dr. Smith’s Adult Ointment have been divested.
In addition, marketing rights have been licensed by Mission to MainPointe for the following Calcet, Fosfree, Heat Guard, Maxilube and Lycelle Head Lice Removal Kit.
“We look at these agreements as the beginning of an exciting strategic partnership between Mission and MainPointe,” Walsdorf said. “Our industry is continually evolving and we hold strong to the belief that partnering for success is more essential today than ever before.”
The new portfolio of products joins Nexafed and Nexafed Sinus as core MainPointe Pharmaceuticals OTC products being supplied by the manufacturer. This past fall, MainPointe acquired the rights to these popular diversion-resistant cough/cold products from Acura Pharmaceuticals.
As part of that deal, MainPointe brought Nexafed 2.0 to market late last year.
"Conversion of pseudoephedrine products into methamphetamine remains an acute problem in many communities," John Schutte, MainPointe chairman and CEO, said when MainPoint first acquired the rights to market Nexafed. "The Nexafed products have proven to be a success in curbing this costly problem and we look forward to driving this business forward."